Attorney Docket No. 43512-104209

Client Refernece: 201452

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No.

Tanaka et al.

For:

Group Art Unit: Unassigned

Application No. 10/573,167

Examiner: Unassigned

Filed: March 21, 2006

METHOD FOR CALIBRATING LIGAND

SEPCIFICITY

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a

In re Application of Tanaka et al. Application No. 10/573,167

		ffice Action on the merits; or (d) before the mailing of a first Office Action after ng of a request for continued examination under 37 CFR 1.114.
	37 CF	(a), (b), (c) or (d) above, but before the mailing date of a final action under R 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise prosecution in the application, and includes <i>one</i> of:
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	under and o 37 CF	he mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, nor before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as th in 37 CFR 1.17(p) (see "Fees" below).
	payme contain 37 CF as set t NOTE: 2000, v	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before ant of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after May 29, wherein a paper containing only an Information Disclosure Statement in compliance with 37 and 1.98 is being filed.
Copie	s of the	References
	Copies	s of all of the references listed on the enclosed Form 1449 are enclosed herewith.
	relevant Englis by a for relevant	ed to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an h-language abstract, or an English-language version of the search report or action or preign patent office in a counterpart foreign application indicating the degree of nce found by the foreign office is being submitted in lieu of a concise explanation relevance pursuant to 37 CFR 1.98(a)(3).
\boxtimes	A cop	y of the international search report is enclosed herewith.
	parent furnish submit Exami with t accord an ear	eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were need at that time. Accordingly, additional copies of the references are not teed herewith, so as not to burden the file with duplicate copies of references. The ner is respectfully requested to carefully review the references in accordance he requirements set out in the Manual of Patent Examining Procedure. In sance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for the filing date under 35 USC 120 in which copies of the references were usly furnished are set out below:

In re Application of Tanaka et al. Application No. 10/573,167

Authorization to Charge Additional Fees

 \boxtimes

	U.S. APPLI	atus (check c	ne)					
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED			
1.								
2. 3.								
<u> </u>	ment under 37 CFR	1.97(e)	<u>I</u>		L			
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.							
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.							
State	ment under 37 CFR	1.704(d)						
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.							
Fees								
	No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.							
Meth	od of Payment of Fo	ees						
	Charge Deposit Account No. 12-0913 in the amount of \$.							

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-0913.

In re Application of Tanaka et al. Application No. 10/573,167

Instructions as to Overpayment

Credit Account No. 12-0913.

Refund

Respectfully submitted,

Carol Larcher, Reg. No. 35,243 BARNES & THORNBURG LLP

P.O. Box 2786

Chicago, Illinois 60690-2786 (312) 357-1313 (telephone) (312) 759-5646 (facsimile)

Date: December 29, 2006

Please type a plus sign (+) inside this box ->-	干
---	---

Substitute		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of 1

Complete if Known					
Application Number:	10/573,167				
Filing Date:	March 21, 2006				
First Named Inventor:	Akito Tanaka				
Group Art Unit:	Unassigned				
Confirmation Number:					
Examiner Name:	Unassigned				
Attorney Docket Number:	43512-104209				

				U.S. PATENT DOCUMENTS			
	U.S. Patent Document						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	AA	4,745,072		Ekins et al.	May 17, 1988		
	AB	5,753,518		Karlson	May 19, 1998		
**							

	Foreign Patent Document						Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No⁺⁴
	AC	JP	60-501674	Α	Ekins Roger Philip	Oct. 3, 1985		X⁺
	AD	JP	9-504859	Α	Pharmacia Biosensor AB.	May 13, 1997		X⁺
	AE	JP	10-221341	Α	Mitsui Chemicals, Inc.	Aug. 21, 1998		X ⁺
	AF	JP	2000-074918	Α	Matsushita Electric	Mar. 14, 2000		X ⁺
				-			1	
		-					1	
							 	

- -		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Doc. Include name of the author (in CAPITAL LETTERS), ti		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	Translatio	
Initials	No. magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city country where published.		Yes	No*+

CHDS01 CLARCHER 372493v1

EXAMINER	DATE CONSII	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).